Protalix BioTherapeutics, Inc. (PLX)
USD 1.71
(-1.72%)
USD 1.71
(-1.72%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 0.12 USD | 138.71% |
| 2022 | -0.31 USD | 59.74% |
| 2021 | -0.77 USD | -50.98% |
| 2020 | -0.51 USD | 71.19% |
| 2019 | -1.77 USD | 1.67% |
| 2018 | -1.80 USD | 72.35% |
| 2017 | -6.51 USD | -2144.83% |
| 2016 | -0.29 USD | -147.54% |
| 2015 | 0.61 USD | 290.62% |
| 2014 | -0.32 USD | -6.67% |
| 2013 | -0.30 USD | -130.77% |
| 2012 | -0.13 USD | 69.77% |
| 2011 | -0.43 USD | -19.44% |
| 2010 | -0.36 USD | 12.2% |
| 2009 | -0.41 USD | -36.67% |
| 2008 | -0.30 USD | 91.04% |
| 2007 | -3.35 USD | -946.88% |
| 2006 | -0.32 USD | -7900.0% |
| 2005 | -0.00 USD | 52.94% |
| 2004 | -0.01 USD | 98.23% |
| 2003 | -0.48 USD | 5.88% |
| 2002 | -0.51 USD | 50.0% |
| 2001 | -1.02 USD | -292.31% |
| 2000 | -0.26 USD | 86.39% |
| 1999 | -1.91 USD | 23.9% |
| 1998 | -2.51 USD | -634.04% |
| 1997 | 0.47 USD | -22.95% |
| 1996 | 0.61 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.06 USD | 24.03% |
| 2024 Q2 | -0.03 USD | 52.15% |
| 2023 Q1 | -0.05 USD | 25.14% |
| 2023 FY | - USD | 138.71% |
| 2023 Q3 | -0.03 USD | -108.83% |
| 2023 Q2 | 0.29 USD | 632.11% |
| 2023 Q4 | -0.08 USD | -223.44% |
| 2022 Q1 | -0.06 USD | 60.6% |
| 2022 Q2 | -0.11 USD | -86.13% |
| 2022 Q3 | -0.08 USD | 26.36% |
| 2022 FY | - USD | 59.74% |
| 2022 Q4 | -0.07 USD | 10.12% |
| 2021 Q2 | -0.25 USD | -78.57% |
| 2021 Q1 | -0.14 USD | -1257.02% |
| 2021 Q3 | -0.09 USD | 63.12% |
| 2021 FY | - USD | -50.98% |
| 2021 Q4 | -0.15 USD | -62.69% |
| 2020 Q4 | 0.01 USD | 108.64% |
| 2020 Q1 | 0.10 USD | 498.8% |
| 2020 Q2 | -0.13 USD | -230.0% |
| 2020 Q3 | -0.14 USD | -7.69% |
| 2020 FY | - USD | 71.19% |
| 2019 Q3 | -0.24 USD | 53.85% |
| 2019 FY | - USD | 1.67% |
| 2019 Q1 | -0.49 USD | -174.24% |
| 2019 Q2 | -0.52 USD | -6.12% |
| 2019 Q4 | 0.02 USD | 106.96% |
| 2018 Q4 | 0.66 USD | 162.86% |
| 2018 Q3 | -1.05 USD | -36.36% |
| 2018 Q1 | -0.65 USD | 39.81% |
| 2018 FY | - USD | 72.35% |
| 2018 Q2 | -0.77 USD | -18.46% |
| 2017 FY | - USD | -2144.83% |
| 2017 Q2 | 0.04 USD | 100.74% |
| 2017 Q4 | -1.08 USD | -25.58% |
| 2017 Q3 | -0.86 USD | -2536.26% |
| 2017 Q1 | -4.75 USD | -2161.9% |
| 2016 Q1 | -0.09 USD | -101.18% |
| 2016 Q3 | -0.07 USD | 33.64% |
| 2016 Q2 | -0.11 USD | -27.61% |
| 2016 FY | - USD | -147.54% |
| 2016 Q4 | -0.21 USD | -187.67% |
| 2015 Q2 | -0.05 USD | 15.44% |
| 2015 FY | - USD | 290.62% |
| 2015 Q4 | 7.31 USD | 18060.69% |
| 2015 Q3 | -0.04 USD | 24.91% |
| 2015 Q1 | -0.06 USD | 92.96% |
| 2014 FY | - USD | -6.67% |
| 2014 Q4 | -0.91 USD | -955.68% |
| 2014 Q1 | -0.08 USD | 93.29% |
| 2014 Q3 | -0.09 USD | -30.8% |
| 2014 Q2 | -0.07 USD | 16.79% |
| 2013 Q1 | -0.05 USD | 95.62% |
| 2013 Q3 | -0.06 USD | 16.06% |
| 2013 FY | - USD | -130.77% |
| 2013 Q4 | -1.18 USD | -1797.11% |
| 2013 Q2 | -0.07 USD | -58.0% |
| 2012 FY | - USD | 69.77% |
| 2012 Q4 | -1.07 USD | -1695.3% |
| 2012 Q3 | -0.06 USD | -154.18% |
| 2012 Q1 | -0.07 USD | 93.35% |
| 2012 Q2 | 0.11 USD | 263.69% |
| 2011 Q3 | -0.10 USD | 37.5% |
| 2011 Q2 | -0.16 USD | -158.9% |
| 2011 Q1 | -0.06 USD | 94.06% |
| 2011 Q4 | -1.01 USD | -910.0% |
| 2011 FY | - USD | -19.44% |
| 2010 Q2 | -0.12 USD | -21.95% |
| 2010 Q3 | -0.03 USD | 74.5% |
| 2010 FY | - USD | 12.2% |
| 2010 Q4 | -1.04 USD | -3298.69% |
| 2010 Q1 | -0.10 USD | 94.68% |
| 2009 Q4 | -1.85 USD | -2302.6% |
| 2009 Q3 | -0.08 USD | -8.15% |
| 2009 Q2 | -0.07 USD | -4.4% |
| 2009 FY | - USD | -36.67% |
| 2009 Q1 | -0.07 USD | 92.16% |
| 2008 Q2 | -0.06 USD | 17.36% |
| 2008 FY | - USD | 91.04% |
| 2008 Q4 | -0.87 USD | -916.36% |
| 2008 Q1 | -0.07 USD | 90.37% |
| 2008 Q3 | -0.09 USD | -53.68% |
| 2007 Q2 | -1.92 USD | -255.56% |
| 2007 FY | - USD | -946.88% |
| 2007 Q4 | -0.70 USD | 2.78% |
| 2007 Q3 | -0.72 USD | 62.5% |
| 2007 Q1 | -0.54 USD | 62.76% |
| 2006 Q2 | -0.10 USD | -16566.67% |
| 2006 Q1 | -0.00 USD | 99.82% |
| 2006 FY | - USD | -7900.0% |
| 2006 Q4 | -1.45 USD | -34423.81% |
| 2006 Q3 | -0.00 USD | 95.8% |
| 2005 FY | - USD | 52.94% |
| 2005 Q4 | -0.34 USD | -209.09% |
| 2005 Q3 | -0.11 USD | -151.14% |
| 2005 Q2 | -0.04 USD | -23.38% |
| 2005 Q1 | -0.04 USD | 96.71% |
| 2004 Q3 | -0.15 USD | 25.0% |
| 2004 Q1 | -0.09 USD | 94.2% |
| 2004 Q2 | -0.20 USD | -118.34% |
| 2004 Q4 | -1.08 USD | -620.0% |
| 2004 FY | - USD | 98.23% |
| 2003 Q1 | -0.11 USD | 93.53% |
| 2003 FY | - USD | 5.88% |
| 2003 Q2 | -0.10 USD | 9.09% |
| 2003 Q3 | -0.11 USD | -10.0% |
| 2003 Q4 | -1.58 USD | -1336.36% |
| 2002 Q1 | -0.12 USD | 93.75% |
| 2002 Q2 | -0.11 USD | 8.33% |
| 2002 Q4 | -1.70 USD | -1445.45% |
| 2002 Q3 | -0.11 USD | 0.0% |
| 2002 FY | - USD | 50.0% |
| 2001 Q3 | -0.17 USD | 0.0% |
| 2001 FY | - USD | -292.31% |
| 2001 Q2 | -0.17 USD | 61.36% |
| 2001 Q1 | -0.44 USD | 73.17% |
| 2001 Q4 | -1.92 USD | -1029.41% |
| 2000 Q3 | 0.32 USD | 1163.12% |
| 2000 FY | - USD | 86.39% |
| 2000 Q1 | -0.10 USD | 98.9% |
| 2000 Q4 | -1.64 USD | -612.5% |
| 2000 Q2 | -0.03 USD | 69.57% |
| 1999 Q2 | -0.07 USD | 89.22% |
| 1999 Q1 | -0.63 USD | 95.75% |
| 1999 FY | - USD | 23.9% |
| 1999 Q4 | -9.02 USD | -1997.67% |
| 1999 Q3 | -0.43 USD | -533.28% |
| 1998 Q1 | -20.00 USD | -5.26% |
| 1998 Q2 | -1.00 USD | 95.0% |
| 1998 Q3 | -0.17 USD | 83.0% |
| 1998 Q4 | -14.83 USD | -8623.53% |
| 1998 FY | - USD | -634.04% |
| 1997 Q2 | -14.00 USD | -40.0% |
| 1997 Q3 | -20.00 USD | -42.86% |
| 1997 Q4 | -19.00 USD | 5.0% |
| 1997 FY | - USD | -22.95% |
| 1997 Q1 | -10.00 USD | -474.53% |
| 1996 FY | - USD | 0.0% |
| 1996 Q3 | 1.00 USD | 0.0% |
| 1996 Q4 | 2.67 USD | 167.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -0.60 USD | 120.0% |
| Ampio Pharmaceuticals, Inc. | -10.67 USD | 101.125% |
| Armata Pharmaceuticals, Inc. | -1.91 USD | 106.283% |
| Actinium Pharmaceuticals, Inc. | -1.83 USD | 106.557% |
| Azitra, Inc. | -54.76 USD | 100.219% |
| Can-Fite BioPharma Ltd. | -1.79 USD | 106.704% |
| Chromocell Therapeutics Corporation | -1.28 USD | 109.375% |
| Calidi Biotherapeutics, Inc. | -1.73 USD | 106.936% |
| CEL-SCI Corporation | -0.73 USD | 116.438% |
| iBio, Inc. | -6.50 USD | 101.846% |
| Lineage Cell Therapeutics, Inc. | -0.12 USD | 200.0% |
| MAIA Biotechnology, Inc. | -1.49 USD | 108.054% |
| Matinas BioPharma Holdings, Inc. | -5.28 USD | 102.273% |
| Navidea Biopharmaceuticals, Inc. | -0.59 USD | 120.339% |
| NovaBay Pharmaceuticals, Inc. | -138.65 USD | 100.087% |
| NanoViricides, Inc. | -0.70 USD | 117.143% |
| Oragenics, Inc. | -9.18 USD | 101.307% |
| BiomX Inc. | -5.10 USD | 102.353% |
| BiomX Inc. | -5.10 USD | 102.353% |
| Palatin Technologies, Inc. | -2.02 USD | 105.941% |
| Scorpius Holdings, Inc. | -347.20 USD | 100.035% |